---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-070385"
form_type: "8-K"
ticker: "IRIX"
cik: "0001006045"
company_name: "IRIDEX CORP"
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T12:18:17.964895+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Iridex Q1 revenue $11.9M, positive adj EBITDA $0.4M after $10M strategic investment

## Summary
- Total revenue $11.9M (flat YoY); Cyclo G6 glaucoma revenue up 8% to $3.2M; Retina revenue down 3% to $6.6M.
- Adjusted EBITDA improved to $0.4M from ($2.5M) YoY; net loss narrowed to $1.7M ($0.10/share) from $3.5M ($0.21).
- Operating expenses cut 32% to $5.3M; gross margin expanded to 42.5% from 37.9% on favorable product mix.
- Received $10M strategic investment from Novel Inspiration; Lind note payable settled, reducing debt.
- 2025 outlook: cash flow breakeven and positive adjusted EBITDA on 2024-level revenue.

## SEC filing metadata
- accession: 0000950170-25-070385
- form_type: 8-K
- ticker: IRIX
- cik: 0001006045
- company_name: IRIDEX CORP
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006045/000095017025070385/0000950170-25-070385-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006045/000095017025070385/irix-20250513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-070385
- JSON: https://secwatch.observer/filing/0000950170-25-070385.json
- Plain text: https://secwatch.observer/filing/0000950170-25-070385.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.